ACAD Acadia Pharmaceuticals (ACAD) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001070494
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
189
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $359.3K priced
What the filings say about ACAD
Insiders, 180 days
-$1.5M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$158.8K
1 notice
Acadia Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ACADIA PHARMACEUTICALS INC insiders sold a net $1.5M of stock across 138 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Aug 5, 2026.
- The trade is 6.5% of the 77,120 shares held after it.
- 1 other insider sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold about $145.0K of ACAD on Aug 6, 2026; 1 other insider sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Aug 5, 2026.
- The trade is 13.7% of the 67,828 shares held after it.
- 1 other insider sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold about $272.6K of ACAD on Aug 6, 2026; 1 other insider sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on May 4, 2026.
- The trade is 8.6% of the 67,828 shares held after it.
- 1 other insider sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold about $169.6K of ACAD on Aug 5, 2026; 1 other insider sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 25, 2026.
- The trade is 86.7% of the 19,044 shares held after it.
- 1 other insider sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Head of Research & Dev Thompson Elizabeth H.Z. sold about $431.4K of ACAD on Jul 30, 2026; 1 other insider sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 25, 2026.
- The trade is 0.3% of the 18,994 shares held after it.
- 1 other insider sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Head of Research & Dev Thompson Elizabeth H.Z. sold about $1.3K of ACAD on Jul 30, 2026; 1 other insider sold within 30 days and 189 funds added in the latest 13F quarter.138 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.5M over 180 days
-$1.0M over 90 days
below 66% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
189 funds bought in last quarter
more than 88% of Pharma & Biotech
Revenue
+11.9% year over year
more than 62% of Pharma & Biotech
Margin
36.5% net margin
more than 93% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.5% of the float short (float per yahoo 2026-10-26) · 2.9 days to cover · settled 2026-09-30
more than 50% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ACAD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-7.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ACAD: institutional holders (13F)
13F holdings, latest reported quarter
42,912,904 sh
$1.1B
22,515,173 sh
$569.6M
9,076,212 sh
$229.6M
8,838,450 sh
$223.6M
7,144,524 sh
$180.8M
Congress trades in ACAD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ACAD planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Schneyer Mark C.
Filed 2026-08-05
$158.8K
Kihara James
Filed 2026-06-26
$297.0K
ACAD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALGER WEATHERBIE SPECIALIZED GROWTH FUND
$9.3M position · as of 2026-07-31
3.9%
Invesco Biotechnology & Genome ETF
$8.5M position · as of 2026-07-31
3.0%
ALPS Medical Breakthroughs ETF
$3.8M position · as of 2026-05-31
2.4%
Virtus Biotech Etf
$1.7M position · as of 2026-07-31
1.7%
Allspring SMID Core ETF
$1.7M position · as of 2026-06-30
1.5%
Invesco S&P SmallCap Health Care ETF
$1.9M position · as of 2026-05-31
1.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
21 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 2
2 active
11
Phase 3
2 active
1
Phase 4
0 active
4
Multi-phase
1 active
What changed recently
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrom
2026-10-16 · Active Not Recruiting → Completed
Phase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
2026-09-30 · Enrolling By Invitation → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Stephen RDavis
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$7.6M
$21.0M
$3.0M
-41%
-8%
2022
$14.0M
$7.7M
$4.3M
-70%
-11%
2021
$9.8M
-$21.5M
$3.0M
-56%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.5M sold by insiders over 180 days, 189 funds added last quarter, $158.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ACAD financials
Revenue growth
+11.9%
XBRL, annual
Net margin
36.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ACAD
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | $957.8M |
| FY Dec 2023 | $726.4M |
| FY Dec 2022 | $517.2M |
| FY Dec 2021 | $484.1M |
| Jun 2026 | $308.0M |
| Mar 2026 | $268.1M |
| Dec 2025 | $284.0M |
| Sep 2025 | $278.6M |
| Jun 2025 | $264.6M |
| Mar 2025 | $244.3M |
| Dec 2024 | $259.6M |
| Sep 2024 | $250.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+33.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ACAD
| FY Dec 2025 | +36.5% |
| FY Dec 2024 | +23.6% |
| FY Dec 2023 | -8.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -34.7% |
| Jun 2026 | +10.2% |
| Mar 2026 | +1.4% |
| Dec 2025 | +96.3% |
| Sep 2025 | +25.8% |
| Jun 2025 | +10.1% |
| Mar 2025 | +7.8% |
| Dec 2024 | +55.2% |
| Sep 2024 | +13.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$145.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ACAD
| FY Dec 2025 | $105.1M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$114.0M |
| FY Dec 2021 | -$126.8M |
| Jun 2026 | $95.7M |
| Mar 2026 | $28.8M |
| Dec 2025 | -$52.7M |
| Sep 2025 | $73.9M |
| Jun 2025 | $63.7M |
| Mar 2025 | $20.3M |
| Dec 2024 | $39.9M |
| Sep 2024 | $63.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ACAD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ACAD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+35.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ACAD
| FY Dec 2025 | +39.9% |
| FY Dec 2024 | +38.8% |
| FY Dec 2023 | -14.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -28.7% |
| Jun 2026 | +35.7% |
| Mar 2026 | +37.3% |
| Dec 2025 | +39.9% |
| Sep 2025 | +34.9% |
| Jun 2025 | +33.1% |
| Mar 2025 | +37.2% |
| Dec 2024 | +38.8% |
| Sep 2024 | +27.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+25.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ACAD
| FY Dec 2025 | +28.4% |
| FY Dec 2024 | +23.3% |
| FY Dec 2023 | -9.2% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -22.6% |
| Jun 2026 | +25.6% |
| Mar 2026 | +27.4% |
| Dec 2025 | +28.4% |
| Sep 2025 | +22.6% |
| Jun 2025 | +20.7% |
| Mar 2025 | +23.0% |
| Dec 2024 | +23.3% |
| Sep 2024 | +16.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -213%, not meaningful
Return on invested capital ACAD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ACAD
| FY Dec 2025 | +10.1% |
| FY Dec 2024 | +35.8% |
| FY Dec 2023 | -15.3% |
| FY Dec 2022 | -41.9% |
| FY Dec 2021 | -26.6% |
| Jun 2026 | +7.6% |
| Mar 2026 | +7.6% |
| Dec 2025 | +10.1% |
| Sep 2025 | +30.0% |
| Jun 2025 | +32.2% |
| Mar 2025 | +34.7% |
| Dec 2024 | +35.8% |
| Sep 2024 | +21.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
8.85x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ACAD
| FY Dec 2025 | 11.61x |
| FY Dec 2024 | 13.49x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 11.35x |
| Mar 2026 | 10.07x |
| Dec 2025 | 11.61x |
| Sep 2025 | 13.77x |
| Jun 2025 | 16.22x |
| Mar 2025 | 12.12x |
| Dec 2024 | 13.49x |
| Sep 2024 | 19.72x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ACAD
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield ACAD
| FY Dec 2025 | +2.3% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -4.4% |
| FY Dec 2021 | -3.4% |
| Jun 2026 | +3.4% |
| Mar 2026 | +3.0% |
| Dec 2025 | +2.3% |
| Sep 2025 | +5.5% |
| Jun 2025 | +5.2% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.13x
P/E over trailing EPS growth of 68%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ACAD
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.17x |
| Mar 2026 | 0.16x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.14x |
| Jun 2025 | 0.03x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.1B | $957.8M | $726.4M | $517.2M |
| Gross profit | n/a | n/a | $684.8M | $507.1M |
| Operating income | $104.8M | $230.8M | -$73.4M | -$223.6M |
| Net income | $391.0M | $226.0M | -$61.0M | -$214.0M |
| EPS (diluted) | 2.30 | 1.36 | -0.37 | -1.34 |
| Operating cash flow | $109.8M | $157.7M | $16.7M | -$114.0M |
| Cash | $177.7M | $319.6M | $188.7M | $114.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
ACAD Stock Sonar score 5/7 axes
Find similar shapesCompareACAD ranks highest on profitability (91st percentile) and institutional and government (89th), and lowest on insider conviction (16th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ACAD filings, in plain words
Are Acadia Pharmaceuticals insiders buying or selling ACAD?
In the 180 days to 2026-10-27, Acadia Pharmaceuticals insiders were net sellers, a net $1.5M across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of ACAD?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $158.8K of stock; the latest, by Schneyer Mark C., was filed 2026-08-05.
Read the full summary
In the 180 days to 2026-10-27, Acadia Pharmaceuticals insiders were net sellers of ACAD, a net $1.5M across purchases and sales reported on Form 4 by 3 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $158.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
